Some older patients with breast cancer may avoid radiotherapy

Omission of radiotherapy is a reasonable option for women age 65 or older who receive hormone therapy after breast-conserving surgery for hormone receptor-positive, axillary node-negative breast cancer, according to results of the PRIME 2 trial presented at the 2013 San Antonio Breast Cancer Symposium, held Dec. 10-14."Radiotherapy has been known to reduce the risk of breast cancer recurrence three- to fourfold.
Source: Health News from Medical News Today - Category: Consumer Health News Tags: Breast Cancer Source Type: news

Related Links:

ConclusionsThe results of this study showed that lung volume changes were not a cause for concern in breast cancer patients. There are three reasons to support this conclusion. Lung volume changes and percentage reductions in LVP for each Gy increase of MLD and each percentage increase of V20 in each lobe were small; patients were asymptomatic during the follow-up period; and LVP showed partial improvements after 6 months.
Source: Reports of Practical Oncology and Radiotherapy - Category: Cancer & Oncology Source Type: research
ConclusionsBreast conservation may be considered a safe alternative in the surgical treatment of MBC. Future research should focus on better standardization of local therapy for MBC and improved reporting of outcomes.
Source: Annals of Surgical Oncology - Category: Cancer & Oncology Source Type: research
AbstractBackgroundAim: To clarify the clinicopathological characters and treatments and prognosis in elderly breast cancer patients using the Japanese Breast Cancer Registry (JBCR) system.MethodsWe reviewed data from JBCR, which is the nation-wide registry of newly diagnosed and operated primary breast cancer patients in Japan. To clarify its characteristics, we compared elderly patients aged 75 and over (elderly) with aged from 65 to 74 (young-old; y-o) and that from 55 to 64 (post-menopausal; p-m), respectively.ResultsIn total 132,240 cases diagnosed between 2004 and 2011 were reviewed (elderly; n  = 27,385...
Source: Annals of Oncology - Category: Cancer & Oncology Source Type: research
AbstractBackgroundImmune checkpoint inhibition (ICI) is synergistic with HER2-directed therapy in pre-clinical models. Clinically, pembrolizumab (K)-mediated ICI plus HER2-directed therapy with trastuzumab (H) is safe and demonstrated modest activity in H-resistant HER2-positive (HER2+) metastatic breast cancer. Because ICI may confer more robust activity when administered earlier in the course of disease, HER2-directed therapy with ICI administered in the curative-intent, treatment-naive setting may allow for de-escalation of cytotoxic backbones; confer life-long, tumor-specific immunity; and ultimately, improve cure rate...
Source: Annals of Oncology - Category: Cancer & Oncology Source Type: research
Conclusion: Early stage breast cancer patients were evaluated by a surgeon, radiation oncologist and medical oncologist less than 75% of the time. Enhanced coordination of care and navigation programs may improve the quality of care delivered. PMID: 31296072 [PubMed - as supplied by publisher]
Source: Cancer Investigation - Category: Cancer & Oncology Tags: Cancer Invest Source Type: research
CONCLUSIONS: Among the patients with invasive carcinoma or DCIS within less than 1 mm from the resection margin, adjuvant RT with higher dose > 66Gy EQD2 might improve local control. Further prospective studies are warranted to validate the benefit and risk of a high dose boost after BCS in patients with a positive resection margin. PMID: 31265973 [PubMed - as supplied by publisher]
Source: Breast - Category: Cancer & Oncology Authors: Tags: Breast Source Type: research
ConclusionsOur study found that in a multidisciplinary breast cancer centre where all three breast ablative and reconstruction options are available to  early breast cancer patients, either BCS or IBR can be used to provide patients with a higher degree of satisfaction and psychosocial well-being compared with MA in the long-term.
Source: Annals of Surgical Oncology - Category: Cancer & Oncology Source Type: research
Publication date: Available online 15 March 2019Source: European Journal of Surgical OncologyAuthor(s): Elizabeth S. Morrow, Sheila Stallard, Julie Doughty, Andy Malyon, Matthew Barber, J. Michael Dixon, Laszlo RomicsAbstractIntroductionThe role of oncoplastic breast conservation (OBC) surgery is not fully defined in terms of whether it is equivalent to standard breast conservation (SBC), or more an alternative to mastectomy, or whether it occupies its own niche somewhere between the two. Therefore, we have carried out a population-based prospective audit of the current OBC practice in Scotland.MethodsAll patients diagnose...
Source: European Journal of Surgical Oncology (EJSO) - Category: Surgery Source Type: research
AbstractPurpose of ReviewDuctal carcinoma in situ (DCIS; intraductal carcinoma) of the breast is commonly found in an asymptomatic woman on routine screening mammography. The purpose of this review is to describe current approaches to the management of DCIS as well as areas for future investigation.Recent FindingsRandomized trials have demonstrated that adding radiation treatment after breast conservation surgery (lumpectomy; surgical excision) reduces the rate of ipsilateral local recurrence by about half, and that adding hormonal therapy reduces the rate of all breast cancer events (ipsilateral plus contralateral). Early...
Source: Current Oncology Reports - Category: Cancer & Oncology Source Type: research
ConclusionsThe local recurrence risk reduction of the tumour bed boost in breast-conserving therapy is not influenced by the applied boost technique.
Source: Strahlentherapie und Onkologie - Category: Cancer & Oncology Source Type: research
More News: Breast Cancer | Breast Conservation Surgery | Cancer | Cancer & Oncology | Health | Hormonal Therapy | Hormones | Women